Redeye updates its view of Curasight following the Q1 report and recent events in the company.
Trots en svag start på året bibehåller vi vår optimistiska syn inför andra halvåret 2024 och kommand...
Redeye updates on Embracer following Q4-results where adjusted EBIT was in line with our expectation...
Redeye comments on Scandion Oncology’s Q1 2024 report, shortly after the company announced final ter...
Embellence Group uppvisar stark tillväxt under Q1. EBITA-resultat förbättrades, delvis tack vare pri...
Cereno Scientific’s Q124 results provided a financial update and recapped the company’s clinical pla...
ChargePanel AB (”ChargePanel” eller ”Bolaget”) uppvisade under helåret 2023 en hög affärsaktivitet o...
BioInvent will present new positive data for BI-1206 in solid tumours and BI-1808 at ASCO.
'24e-'26e EBITDA cut by 14-1% Near-term margin pressure driven by business transformation '24e EV/EB...
Redeye updates on Northbaze following its Q1 results, which were weaker than expected on the topline...
Redeye saw a report with more robust sales and results than expected.
Redeyes’ long-term view of Dignitana is intact despite the flat sales progression.
Calliditas delivers a positive surprise in patient enrolment (18% above our expectations) and new su...
Penetration improves further, private jet deal possible in H2'24 OEM to drive ~20-30% EBIT growth in...
CEO spoke about acquisition synergies Group collaboration could drive growth and margins Thebalux ac...
Redeye comments on Tango Therapeutics' discontinuation of the USP1 programme (TNG348), which does no...
STENOCARE announced on May 23rd that the company’s premium product, the Astrum oil, is ready for lau...
Under de senaste åren har Zoomability investerat i verksamheten för att kunna exekvera på Bolagets t...
Nettoomsättningen för det första kvartalet uppgick till 1,99 MSEK (0,43) och EBIT uppgick till –7,92...
Starkt kvartal över förväntan Under kv1 2024 levererade Fable Media en nettoomsättning i linje med...
